AEI joins int’l LASIK conference
Asian Eye Institute (AEI) stood out among LASIK centers in the
LASIK stands for laser-assisted in situ keratomileusis, a surgical procedure to reduce dependency on glasses and contact lenses.
At the conference, Ang compared the new Zyoptix Personalized Aspheric Treatment software to previously available treatments.
The new technology addresses four areas of concern in LASIK — nearsightedness, astigmatism, and pre-existing and induced higher-order aberrations — leading to better vision quality, less glare and halos, and better night-time vision.
It is an advanced and sophisticated algorithm that improves post-LASIK outcomes and patient satisfaction.
AEI was one of four study sites, along with two eye centers in
Ang is the only Philippine representative to the Asian Refractive Committee (ARC), composed of the finest LASIK surgeons in
The ARC is the advisory body for product and technology development for B&L LASIK platforms.
The Zyoptix system used at AEI takes LASIK to a new frontier and makes treatment unique to each eye, thus addressing individual vision errors.
Dr. Hung Ming Lee of
This feature adjusts for eye movement within 15 degrees in any direction during surgery, movement within 15 degrees in any direction during surgery, thus ensuring that the laser beam is always aimed at the correct intended spot on the cornea. This translates to peace of mind and better safety and outcomes for both patients and surgeon.
Prof. Hungwon Tchah of the
In this procedure, a specially designed instrument called the Zyoptix XP Epitome is used to create a thin flap of corneal epithelium, benefiting patients with thin corneas and dry eye syndrome and for patients who actively play sports or are military personnel.
The AEI was part of the field observation study that B&L conducted when they introduced the new Zyoptix XP Epitome, and is now in the process of acquiring this technology to make it available for patients.
Experts also discussed progress on two new technology solutions for presbyopic patients (those who need reading glasses).
These are the B&L Crystalens, the first FDA-approved accommodating intraocular lens, and the Acufocus Kamra Inlay, a corneal device now undergoing clinical trials in preparation for FDA approval.
The AEI is participating in the Acufocus multi-center clinical trial.
Aside from Ang, AEI research coordinator Irene Tam, O.D., and AEI optometrist Ruby Chua, O.D., also attended the Zyoptix Alliance.
To serve its patients better, the AEI provides its personnel with opportunities to go abroad and learn state-of-the-art eye care and treatment technologies.
Ang was also a speaker at the World Ophthalmology Congress in
- Latest